Experimental allergic encephalomyelitis is a T-cell-mediated, major histocompatibility complex (MHC) MATERIALS AND METHODS Mice. Female SJL/J mice were purchased from The Jackson Laboratory and were used between 8 and 12 weeks of age.
class H gene-linked autoimmune demyelinating disease of the central nervous system. To develop therapies that will specifically inactivate only the autoantigen-reactive T cells, mice were treated with soluble MHC class II molecules that had been complexed with encephalitogenic peptides. Intravenous iujections of 300 #g of complexes consisting of encephalitogenic peptide 91-103 of myelin basic protein plus I-AS protein on day 0, 4, and 7 were effective in preventing experimental allergic encephalomyelitis. Similarly, administration of 45 gg of I-A' protein complexed to peptide 139-151 from proteolipoprotein on day 1, 4, and 7 prevented mortality and significantiy reduced paralysis induced by immunization with the encephalitogenic proteolipoprotein peptide. Histological examination of sections of animal brains revealed that treatment with I-AS protein plus myelin basic protein 91-103 peptide prevents the development of inflammatory lesions characteristic of experimental allergic encephalomyelitis. Thus, treatment with MHC-self-peptide complexes could serve as a highly specific therapeutic modality in treating autoimmune disease when the putative autoantigen and the MHC restricting elements are known.
The T-cell receptor is composed of an individually specific heterodimeric glycoprotein receptor complex (a3) that binds to antigenic fragments associated with major histocompatibility complex (MHC) molecules (1) (2) (3) (4) . The signals generated by the molecular triad formed by the T-cell receptor, antigenic peptide, and MHC antigens are critical in understanding the mechanism(s) of T-cell activation. Delivery of at least two separate signals is required to activate T cells (5, 6) . (i) The T-cell receptor must bind to the complex of antigenic peptide bound to self-MHC protein, and (ii) simultaneous delivery of an as-yet-undefined costimulatory signal by antigen-presenting cells seems necessary for T-cell activation (5, 6) . Prior studies have suggested that binding of T cells to the MHC-peptide complex on planar membranes in the absence of costimulatory signal(s) leads to T-cell inactivation and the subsequent development of antigen-specific tolerance, referred to as clonal anergy (7) . This situation suggests that occupancy ofantigen-specific T cells with soluble MHCantigen (peptide) complexes will lead to the development of antigen-specific inactivation in vitro and in vivo. If true in vivo, then one might be able to inactivate autoantigen-specific T cells in vivo during an autoimmune disease for which the MHC locus and putative disease-inducing autoantigens were known. We chose murine experimental allergic encephalomyelitis (EAE), which shows clinical and pathological similarities to human multiple sclerosis, as an experimental model system to test this hypothesis.
EAE is a T-cell-mediated, paralytic, autoimmune demyelinating disease of the central nervous system that can be induced in a number of susceptible strains of mice by the injection of either myelin basic protein (MBP) or proteolipoprotein (PLP) (8) (9) (10) (11) (12) . In SJL mice the T-cell responses to peptide determinants are associated with the class II (I-As) allele ofthe MHC class II complex. Encephalitogenic regions of MBP and PLP correspond to peptides 91-103 of MBP and 139-151 of PLP (13, 14 concentration of 12 mM, and I-AS was concentrated by using an Amicon Centriprep-10 concentrator. Purified I-AS was >98% pure based on silver staining of SDS/PAGE gels.
Preparation of MHC-Peptide Complexes. I-AS protein at 1 mg/ml was incubated with 50-fold molar excess of MBP or PLP peptides at 37TC for 48 hr. The excess peptide was removed by extensive dialysis of the complex against PBS/ 0.1% octyl glucoside, a concentration easily tolerated by mice. There was no significant aggregation of complex preparations in 0.1% octyl glucoside as assessed by gel-filtration studies. Percent of I-AS occupancy with peptide ranged from 20 to 30 as determined by a parallel pilot experiment using radiolabeled peptide as described in detail elsewhere (17) . The absence of endotoxin in the final complex preparation was confirmed by Limulus amebocyte lysate procedure as described by Whittaker Bioproducts. T-Cell Clone. HS1 cells were cloned from MBP 91-103-reactive encephalitogenic T-cell line as described (18 
RESULTS AND DISCUSSION
To determine the effect of soluble MHC-peptide complexes on T-dell activation in vitro, a clone derived from MBP 91-103-reactive T-cell line was generated from SJL mice (18) . HS1 cells were depleted of antigen-presenting cells and incubated with I-AS protein plus MBP 91-103 complex at a concentration of 10 ,ug/ml for 24 hr. Fig. 1 (Fig. 2) . In contrast, all four animals that received the I-A' protein plus MBP 1-14, and six of seven animals that received PBS developed paralysis (Fisher's exact test, P < 0.05). In the former group, mean onset of disease was on day 9.7, and in the latter group it was day 9.0 with mean severity of 2.3 and 2.5, respectively. Injection of free peptide at a concentration at least five times greater than that complexed to class II MHC molecules did not prevent EAE development nor did it prevent development of in vitro tolerance (21) . Histological analysis was done from four animals in the I-As protein plus MBP 1-14-treated group and four animals in the I-AS protein plus MBP 91-103-treated groups. Overall 14 perivascular cuffs were identified in the I-AS protein plus MBP 1-14 group, whereas the I-As protein plus MBP 91-103 group showed only 3 cuffs. Most of the inflammation was seen mainly in the periventricular area and in the white matter of the cerebellum (Fig. 3) .
We next addressed the question of whether inhibition of disease induction was possible with other autoantigens presented by the I-A' allele. SJL mice were immunized with peptide 139-151 of PLP in complete Freund's adjuvant to induce EAE. Table 1 shows that animals that received the appropriate I-As protein plus PLP 139-151 peptide complex were protected from the severe fulminant paralytic disease induced by the immunization with peptide in adjuvant. There was no mortality in the I-As peptide plus PLP 139-151 peptide-treated group. Although all six aniiiias did develop paralysis, the mean severity of-animals paralyzed was 2.2, and the mean day of onset was 10.6. In contrast, all six animals that received I-As protein. alone had a mean day of onset of8.2. Five animals died by day 11, and one animal died on day 21. Animals that received saine or no treatment had a mortality of 87%, and the average day of onset was 9.2 (P <0.0001 I-Al protein plus PLP 139-151 versus no treatment; P < 0.0007 I-AS protein plus PLP 139-151 versus I-Al protein alone).
Our observations indicate that in vivo therapy with I-AS protein plus MBP 91-103 complexes (300 pAg) results in the prevention of EAE induced by adoptive transfer of encephalitogenic T-cell lines. In addition, therapy with 45 jug of I-Al protein plus PLP 139-151 significantly lowered the mortality and morbidity in animals that received this therapy. Fluo rescein-activated cell sorter analysis of T-cell subset distribution on spleen and lymph nodes failed to show any significant differences in their numbers, and on day 20 or at the time of sacrifice, there was no difference in the proliferative response to mitogens and alloantigens between the three treatment groups (data not shown).
Our current experiments were designed to determine whether treatment with I-A protein plus peptide complexes could alter the course of disease after activation of encephalitogenic T cells in vivo. Although the in vitro studies with MBP-specific T cells have led us to conclude that induction of anergy occurs after incubation of antigen-specific T cells with MHC-peptide complexes in vitro, the mechanism of action of MHC-peptide complexes in the prevention of EAE In vivo remains to be elucidated. Because EAE is a T-cellmediated disease, many strategies have been attempted to either eliminate or inactivate encephalitogenic T-cell clones as a means of both preventing and treating established disease. At the T-cell level, therapies such as T-cell vaccination (22), immunotherapy with anti-T-ceill receptor antibody (23) , and immunization with peptides that span'the hypervariable regions of the T-cell receptor as immunogens have been successful in prevention of EAE in rats (24, 25) .
Althoughthis form oftherapy is attractive, it assumes that the encephalitogenic T.cell receptor repertoire is very limited.
This assumption appears not to be the case, at least in the SJL strain of mice, in which at least three different variable region (-chain genes are known to be used in the T-cell response to MBP 91-101 (26) . Furthermore, in patients with multiple sclerosis the T-cell response to MBP 86-102, a region overrepresented in multiple sclerosis patients, was not restricted to a particular variable region gene (27, 28) .
At the MHC level, the use ofanti-I-A antibody (29) 
